HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

DIETOTHERAPY AS A PRIORITY TREATMENT POLICY FOR PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE

Download full text PDF
Issue: 
7
Year: 
2017

D. Andreev, Candidate of Medical Sciences; E. Maevskaya, Candidate of Medical Sciences; D. Dicheva, Candidate of Medical Sciences; E. Kuznetsova A.I. Evdokimov Moscow State University of Medicine and Dentistry

The paper analyzes the role of dietotherapy in the treatment of patients with non-alcoholic fatty liver disease (NAFLD). According to current clinical guidelines, dietotherapy and lifestyle changes are the basic treatment policy for patients with NAFLD regardless of its clinical form. A 7-10% weight loss is an obligatory condition for a clinically significant regression of necroinflammatory changes in the liver. The best effect of therapy for NAFLD is achieved through a low-calorie diet in combination with exercises.

Keywords: 
therapy
hepatology
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
liver fibrosis
dietotherapy
diet
treatment
psyllium



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Torres D., Harrison S. Nonalcoholic Fatty Liver Disease. In.: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Edited by M. Feldman, L. Friedman, L. Brandt. 10th ed. 2015.
  2. Maev I.V., Andreev D.N., Dicheva D.T. i dr. Nealkogol'naja zhirovaja bolezn' pecheni: posobie dlja vrachej / M.: PrimaPrint, 2017.
  3. Younossi Z., Koenig A., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. – 2016; 64 (1): 73–84.
  4. Maev I.V., Kucherjavyj Ju.A., Andreev D.N. Ozhirenie i komorbidnost': posobie dlja vrachej / M.: PrimaPrint, 2016.
  5. Bellentani S., Saccoccio G., Masutti F. et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy // Ann. Intern. Med. – 2000; 132 (2): 112–7.
  6. Dam-Larsen S., Franzmann M., Andersen I. et al. Long term prognosis of fatty liver: risk of chronic liver disease and death // Gut. – 2004; 53: 750–5.
  7. Dyson J., Anstee Q., McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging // Frontline Gastroenterol. – 2014; 5 (3): 211–8.
  8. Maev I.V., Andreev D.N. Nealkogol'naja zhirovaja bolezn' pecheni: mehanizmy razvitija, klinicheskie formy i medikamentoznaja korrektsija // Consilium Medicum (Pril. Gastroenterologija). – 2012; 2: 36–9.
  9. Wong V., Wong G., Choi P. et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years // Gut. – 2010; 59: 969–74.
  10. Le M., Devaki P., Ha N. et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States // PLoS One. – 2017; 12 (3): e0173499.
  11. Maev I.V., Kuznetsova E.I., Andreev D.N. i dr. Sovremennye i perspektivnye podhody k diagnostike nealkogol'noj zhirovoj bolezni pecheni // Consilium Medicum. – 2015; 8: 20–7.
  12. Andreev D.N., Dicheva D.T., Kuznetsova E.I. i dr. Nealkogol'naja zhirovaja bolezn' pecheni: lechenie s pozitsij dokazatel'noj meditsiny // Lechaschij vrach. – 2017; 2: 12–8.
  13. European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease // J. Hepatol. – 2016; 64 (6): 1388–402.
  14. Ivashkin V.T., Maevskaja M.V., Pavlov Ch.S. i dr. Klinicheskie rekomendatsii po diagnostike i lecheniju nealkogol'noj zhirovoj bolezni pecheni Rossijskogo obschestva po izucheniju pecheni i Rossijskoj gastroenterologicheskoj assotsiatsii // Ros. zhurn. gastroenterol., gepatol., koloproktol. – 2016; 2: 24–42.
  15. Maev I.V., Gegel' N.V., Dicheva D.T. i dr. Rasstrojstva pischevogo povedenija v svete klinicheskih rekomendatsij po diagnostike i lecheniju nealkogol'noj zhirovoj bolezni pecheni // Consilium Medicum. – 2016; 8: 59–63.
  16. Harrison S., Fecht W., Brunt E. et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial // Hepatology. – 2009; 49: 80–6.
  17. Promrat K., Kleiner D., Niemeier H. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis // Hepatology. – 2010; 51: 121–9.
  18. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L. et al. Weight loss via lifestyle modification significantly reduces features of nonalcoholic steatohepatitis // Gastroenterology. – 2015; 149: 367–78.
  19. Musso G., Cassader M., Rosina F. et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials // Diabetologia. – 2012; 55: 885–904.
  20. Glass L., Dickson R., Anderson J. et al. Total body weight loss of 10% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis // Dig. Dis. Sci. – 2015; 60: 1024–30.
  21. Chalasani N., Younossi Z., Lavine J. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology // Gastroenterology. – 2012; 142: 1592–609.
  22. Professional Practice Committee for the Standards of Medical Care in Diabetes-2016. Obesity management for the treatment oftype 2 diabetes // Diabetes Care. – 2016; 39: 47–51.
  23. Strychar I. Diet in the management of weight loss // CMAJ. – 2006; 174 (1): 56–63.
  24. Fan J., Cao H. Role of diet and nutritional management in nonalcoholic fatty liver disease // J. Gastroenterol. Hepatol. – 2013; 28: 81–7.
  25. Hannah W. Jr., Harrison S. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease // Dig. Dis. Sci. – 2016; 61 (5): 1365–74.
  26. Ouyang X., Cirillo P., Sautin Y. et al. Fructose consumption as a risk factor for nonalcoholic fatty liver disease // J. Hepatol. – 2008; 48: 993–9.
  27. Hsu C., Ness E., Kowdley K. Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease // Adv. Nutr. – 2017; 8 (2): 253–65.
  28. McGavock J., Anderson T., Lewanczuk R. Sedentary lifestyle and antecedents of cardiovascular disease in young adults // Am. J. Hypertens. – 2006; 19: 701–7.
  29. Zhu S., St-Onge M., Heshka S. et al. Lifestyle behaviors associated with lower risk of having the metabolic syndrome // Metab. Clin. Exp. – 2004; 53: 1503–11.
  30. Church T., Kuk J., Ross R. et al. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease // Gastroenterology. – 2006; 130: 2023–30.
  31. Ismail I., Keating S., Baker M. et al. A systematic review and meta-analysis of the effect of aerobic vs. resistance exercise training on visceral fat // Obes. Rev. – 2012; 13 (1): 68–91.
  32. Houghton D., Thoma C., Hallsworth K. et al. Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial // Clin. Gastroenterol. Hepatol. – 2017; 15 (1): 96–102.e3.
  33. Hallsworth K., Fattakova G., Hollingsworth K. et al. Resistance exercise reduces liver fat and its mediators in nonalcoholic fatty liver disease independent of weight loss // Gut. – 2011; 60: 1278–83.
  34. Johnson N., Sachinwalla T., Walton D. et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss // Hepatology. – 2009; 50: 1105–12.
  35. Parker H., Johnson N., Burdon C. et al. Omega-3 supplementation and nonalcoholic fatty liver disease: A systematic review and meta-analysis // J. Hepatol. – 2012; 56: 944–51.
  36. Marik P., Varon J. Omega-3 supplements and the risk of cardiovascular events: A systematic review // Clin. Card. – 2009; 32: 365–72.
  37. Klatsky A., Armstrong M. Alcohol, smoking, coffee, and cirrhosis // Am. J. Epidemiol. – 1992; 136: 1248–57.
  38. Freedman N., Everhart J. et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C // Hepatology. – 2009; 50: (5): 1360–9.
  39. Zelber-Sagi S., Salomone F., Webb M. et al. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population // Transl. Res. – 2015; 165 (3): 428–36.
  40. Wijarnpreecha K., Thongprayoon C., Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis // Eur. J. Gastroenterol. Hepatol. – 2017; 29 (2): 8–12.
  41. Ginzburg M.M. Otchet «Opyt primenenija preparata Mukofal'k v kompleksnoj terapii u patsientov s ozhireniem i metabolicheskim sindromom» NII dietologii i dietoterapii / Samara, 2010.
  42. Komissarenko I.A., Levchenko S.V., Gudkova R.B. i dr. Effekty dlitel'nogo primenenija psilliuma pri lechenii bol'nyh s divertikuljarnoj bolezn'ju tolstoj kishki // Klin. persp. v gastroenterol., gepatol. – 2014; 3: 29–36.
  43. Maevskaja E.A., Maev I.V., Kucherjavyj Ju.A. i dr. Otsenka vlijanija laktulozy ili pischevyh volokon na dinamiku pokazatelej lipidnogo profilja u patsientov s funktsional'nym zaporom i nealkogol'nym steatogepatitom // Lechaschij vrach. – 2016; 4: 117–23.
  44. Anderson J., Allgood L., Turner J. et al. Effects of psyllium on glucose and serum lipid responses in men with type 2 diabetes and hypercholesterolemia // Am. J. Clin. Nutr. – 1999; 70 (4): 466–73.
  45. Gibb R., McRorie J. Jr., Russell D. et al. Psyllium fiber improves glycemic control proportional to loss of glycemic control: a meta-analysis of data in euglycemic subjects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus // Am. J. Clin. Nutr. – 2015; 102 (6): 1604–14.
  46. Giacosa A., Rondanelli M. The right fiber for the right disease: an update on the psyllium seed husk and the metabolic syndrome // J. Clin. Gastroenterol. – 2010; 44 (Suppl. 1): 58–60.
  47. Lambeau K., McRorie J. Jr. Fiber supplements and clinically proven health benefits: How to recognize and recommend an effective fiber therapy // J. Am. Assoc. Nurse Pract. – 2017; 29 (4): 216–23.